Mexican Health Firm Opens $64 Million Texas Plant to Avoid Tariff Risks

2026-08-19 companies

Allen, Tuesday, 18 August 2026.
Omnilife invested $64 million in a Texas facility to hedge against potential 25% import tariffs, relieving its near-capacity Mexican plant while expanding direct access to American consumers.

Strategic Expansion in Texas

Health and wellness company Omnilife has officially opened a new manufacturing and distribution complex in Allen, Texas, marking a significant investment in North American infrastructure [1]. The facility, known as the Omnilife Innovation Park, represents a capital investment exceeding $64 million USD [1][4]. While some reports indicate an inauguration date of August 14, 2026, others confirm the official opening occurred on August 17 or 18, 2026, aligning with the current week’s business announcements [4][5][1]. This strategic move establishes Omnilife’s first manufacturing plant within the United States, complementing existing operations in Guadalajara, Mexico, and Cali, Colombia [5][4]. The United States currently ranks as the company’s third-largest market by sales volume, driving the decision to localize production [1][4].

Facility Specifications and Capacity

The Innovation Park spans approximately 51,097 square meters, equivalent to 550,000 square feet, consolidating corporate offices, logistics, and production into a single location [1][4]. The site is built on LEAN construction principles, featuring LED lighting, efficient electrical systems, and integrated manufacturing logistics [1]. Production areas are classified under ISO 7 and ISO 8 standards, equipped with servo-controlled dosing and automated filling systems [1][5]. An on-site microbiology and analysis laboratory supports quality control within the complex [1][4]. The initial production phase focuses on powdered dietary supplements with a capacity exceeding 500,000 units per year [1][6]. Reserved space within the complex allows for future production lines without requiring additional infrastructure development [1][4].

Mitigating Trade Risks

A primary driver for this expansion is the mitigation of supply chain risks associated with international trade policies, including potential tariffs on imports [5]. Company leadership has cited the need to shield operations from risks tied to potential increases in import taxes or tariffs on Mexican products, which could reach up to 25% [5][2]. Manufacturing within the United States allows the company to remain competitive in the Anglo-Saxon market while avoiding these potential costs [5]. Additionally, local production facilitates partnerships with universities and research centers that require products to be manufactured domestically for scientific backing [5]. The location in Texas provides logistical efficiency toward both coasts and proximity to a large concentration of independent entrepreneurs [5].

Growth Projections

Omnilife plans to scale production significantly over the coming years, with targets to reach 5 million units annually within three years [2][5]. This represents a substantial increase from the initial capacity, calculated as a 900 percent growth potential from the base output [2][1]. Other reports suggest an intermediate scalability to approximately 1.2 million units annually in the initial phase before reaching higher targets [4][5]. The company projects this expansion will reduce capacity utilization at the Guadalajara plant by 18 percentage points over the next five years [5]. This long-term strategy prepares the organization for operations over the next 35 years, focusing on the Hispanic demographic segment with the greatest projected growth in the United States [7][5].

Sources

Manufacturing Supply Chain